4 months in and MASH is still the thing I get wrong
4 months in and MASH is still the thing I get wrong. Numbers below. Ask me the boring questions, they are the useful ones.
Numbers, in the order they matter: 4 months.
What this compound is actually being developed for, since the boards treat it as a weight-loss molecule with a footnote.
It is a dual GLP-1 and glucagon receptor agonist, and the glucagon arm links to hepatic fat and energy expenditure. The headline programme is metabolic liver disease, with endpoints scored on biopsy rather than on a scale.
That matters for how the data should be read. A histological response rate in a biopsy-confirmed population answers a very different question from a mean weight change in an obesity trial, and quoting one in place of the other — which happens in nearly every thread here — is not a comparison.
Bought small because the evidence base is early. That is the only defensible position I could construct.
Not medical advice, obviously, and nothing here is approved for human use. One person with a spreadsheet.
best — the order this archive was captured in
Imaging-derived liver fat fraction is a surrogate. It correlates with histology imperfectly, and a trial reporting one is not reporting the other.
[deleted]
That figure is from the obesity programme, and this thread is about the hepatic one.
It is a dual agonist at the GLP-1 and glucagon receptors. The glucagon arm is associated with increased energy expenditure and with effects on hepatic fat, which is why the development programme is oriented towards liver disease.
Not convinced. Imaging-based fat fraction is not the same as a histological response and the paper is explicit about that.
Small fix — dual agonist, GLP-1 and glucagon. No GIP arm in this molecule.
Cosigning on the glucagon arm. It is the mechanistic thread that connects the hepatic and the metabolic effects.
Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human use.
fibrosis improvement without worsening steatohepatitis is the phrase to learn
Sent a vial to Medutest because there was nothing on file. 99.6% against a claimed 99.0%. First entry for this compound in my own log.
Spent an evening on the histology scoring system and understood the trial literature far better afterwards.